SALARIUS PHARMACEUTICALS ANNOUNCES ISSUANCE OF NEW U.S.
PATENT FOR NEXT-GENERATION TARGETED PROTEIN DEGRADERS
* SALARIUS-CLAIMS COVER COMPOSITION OF MATTER FOR MOLECULAR GLUE DEGRADERS INCLUDING CO'S PRECLINICAL CEREBLON-BINDING COMPOUND,SP-3204,THROUGH SEPT 2037